Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in a higher 2-year rate of progression-free survival than bendamustine in combination with rituximab (85% vs. 36%).
Saved in:
| Published in | The New England journal of medicine Vol. 378; no. 12; pp. 1107 - 1120 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Massachusetts Medical Society
22.03.2018
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in a higher 2-year rate of progression-free survival than bendamustine in combination with rituximab (85% vs. 36%). |
|---|---|
| AbstractList | Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We evaluated the efficacy of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
In this randomized, open-label, phase 3 trial, we randomly assigned 389 patients to receive venetoclax for up to 2 years (from day 1 of cycle 1) plus rituximab for the first 6 months (venetoclax-rituximab group) or bendamustine plus rituximab for 6 months (bendamustine-rituximab group). The trial design did not include crossover to venetoclax plus rituximab for patients in the bendamustine-rituximab group in whom progression occurred. The primary end point was investigator-assessed progression-free survival.
After a median follow-up period of 23.8 months, the rate of investigator-assessed progression-free survival was significantly higher in the venetoclax-rituximab group (32 events of progression or death in 194 patients) than in the bendamustine-rituximab group (114 events in 195 patients); the 2-year rates of progression-free survival were 84.9% and 36.3%, respectively (hazard ratio for progression or death, 0.17; 95% confidence interval [CI], 0.11 to 0.25; P<0.001 by the stratified log-rank test). The benefit was maintained across all clinical and biologic subgroups, including the subgroup of patients with chromosome 17p deletion; the 2-year rate of progression-free survival among patients with chromosome 17p deletion was 81.5% in the venetoclax-rituximab group versus 27.8% in the bendamustine-rituximab group (hazard ratio, 0.13; 95% CI, 0.05 to 0.29), and the 2-year rate among those without chromosome 17p deletion was 85.9% versus 41.0% (hazard ratio, 0.19; 95% CI, 0.12 to 0.32). The benefit of venetoclax plus rituximab over bendamustine plus rituximab was confirmed by an independent review committee assessment of progression-free survival and other secondary efficacy end points. The rate of grade 3 or 4 neutropenia was higher in the venetoclax-rituximab group than in the bendamustine-rituximab group, but the rates of grade 3 or 4 febrile neutropenia and infections or infestations were lower with venetoclax than with bendamustine. The rate of grade 3 or 4 tumor lysis syndrome in the venetoclax-rituximab group was 3.1% (6 of 194 patients).
Among patients with relapsed or refractory chronic lymphocytic leukemia, venetoclax plus rituximab resulted in significantly higher rates of progression-free survival than bendamustine plus rituximab. (Funded by Genentech and AbbVie; ClinicalTrials.gov number, NCT02005471 .). BackgroundVenetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We evaluated the efficacy of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.MethodsIn this randomized, open-label, phase 3 trial, we randomly assigned 389 patients to receive venetoclax for up to 2 years (from day 1 of cycle 1) plus rituximab for the first 6 months (venetoclax-rituximab group) or bendamustine plus rituximab for 6 months (bendamustine-rituximab group). The trial design did not include crossover to venetoclax plus rituximab for patients in the bendamustine-rituximab group in whom progression occurred. The primary end point was investigator-assessed progression-free survival.ResultsAfter a median follow-up period of 23.8 months, the rate of investigator-assessed progression-free survival was significantly higher in the venetoclax-rituximab group (32 events of progression or death in 194 patients) than in the bendamustine-rituximab group (114 events in 195 patients); the 2-year rates of progression-free survival were 84.9% and 36.3%, respectively (hazard ratio for progression or death, 0.17; 95% confidence interval [CI], 0.11 to 0.25; P<0.001 by the stratified log-rank test). The benefit was maintained across all clinical and biologic subgroups, including the subgroup of patients with chromosome 17p deletion; the 2-year rate of progression-free survival among patients with chromosome 17p deletion was 81.5% in the venetoclax-rituximab group versus 27.8% in the bendamustine-rituximab group (hazard ratio, 0.13; 95% CI, 0.05 to 0.29), and the 2-year rate among those without chromosome 17p deletion was 85.9% versus 41.0% (hazard ratio, 0.19; 95% CI, 0.12 to 0.32). The benefit of venetoclax plus rituximab over bendamustine plus rituximab was confirmed by an independent review committee assessment of progression-free survival and other secondary efficacy end points. The rate of grade 3 or 4 neutropenia was higher in the venetoclax-rituximab group than in the bendamustine-rituximab group, but the rates of grade 3 or 4 febrile neutropenia and infections or infestations were lower with venetoclax than with bendamustine. The rate of grade 3 or 4 tumor lysis syndrome in the venetoclax-rituximab group was 3.1% (6 of 194 patients).ConclusionsAmong patients with relapsed or refractory chronic lymphocytic leukemia, venetoclax plus rituximab resulted in significantly higher rates of progression-free survival than bendamustine plus rituximab. (Funded by Genentech and AbbVie; ClinicalTrials.gov number, NCT02005471.) BACKGROUND: Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We evaluated the efficacy of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. METHODS: In this randomized, open-label, phase 3 trial, we randomly assigned 389 patients to receive venetoclax for up to 2 years (from day 1 of cycle 1) plus rituximab for the first 6 months (venetoclax-rituximab group) or bendamustine plus rituximab for 6 months (bendamustine-rituximab group). The trial design did not include crossover to venetoclax plus rituximab for patients in the bendamustine-rituximab group in whom progression occurred. The primary end point was investigator-assessed progression-free survival. RESULTS: After a median follow-up period of 23.8 months, the rate of investigator-assessed progression-free survival was significantly higher in the venetoclax-rituximab group (32 events of progression or death in 194 patients) than in the bendamustine-rituximab group (114 events in 195 patients); the 2-year rates of progression-free survival were 84.9% and 36.3%, respectively (hazard ratio for progression or death, 0.17; 95% confidence interval [CI], 0.11 to 0.25; P\textless0.001 by the stratified log-rank test). The benefit was maintained across all clinical and biologic subgroups, including the subgroup of patients with chromosome 17p deletion; the 2-year rate of progression-free survival among patients with chromosome 17p deletion was 81.5% in the venetoclax-rituximab group versus 27.8% in the bendamustine-rituximab group (hazard ratio, 0.13; 95% CI, 0.05 to 0.29), and the 2-year rate among those without chromosome 17p deletion was 85.9% versus 41.0% (hazard ratio, 0.19; 95% CI, 0.12 to 0.32). The benefit of venetoclax plus rituximab over bendamustine plus rituximab was confirmed by an independent review committee assessment of progression-free survival and other secondary efficacy end points. The rate of grade 3 or 4 neutropenia was higher in the venetoclax-rituximab group than in the bendamustine-rituximab group, but the rates of grade 3 or 4 febrile neutropenia and infections or infestations were lower with venetoclax than with bendamustine. The rate of grade 3 or 4 tumor lysis syndrome in the venetoclax-rituximab group was 3.1% (6 of 194 patients). CONCLUSIONS: Among patients with relapsed or refractory chronic lymphocytic leukemia, venetoclax plus rituximab resulted in significantly higher rates of progression-free survival than bendamustine plus rituximab. (Funded by Genentech and AbbVie; ClinicalTrials.gov number, NCT02005471 .). Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We evaluated the efficacy of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.BACKGROUNDVenetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We evaluated the efficacy of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.In this randomized, open-label, phase 3 trial, we randomly assigned 389 patients to receive venetoclax for up to 2 years (from day 1 of cycle 1) plus rituximab for the first 6 months (venetoclax-rituximab group) or bendamustine plus rituximab for 6 months (bendamustine-rituximab group). The trial design did not include crossover to venetoclax plus rituximab for patients in the bendamustine-rituximab group in whom progression occurred. The primary end point was investigator-assessed progression-free survival.METHODSIn this randomized, open-label, phase 3 trial, we randomly assigned 389 patients to receive venetoclax for up to 2 years (from day 1 of cycle 1) plus rituximab for the first 6 months (venetoclax-rituximab group) or bendamustine plus rituximab for 6 months (bendamustine-rituximab group). The trial design did not include crossover to venetoclax plus rituximab for patients in the bendamustine-rituximab group in whom progression occurred. The primary end point was investigator-assessed progression-free survival.After a median follow-up period of 23.8 months, the rate of investigator-assessed progression-free survival was significantly higher in the venetoclax-rituximab group (32 events of progression or death in 194 patients) than in the bendamustine-rituximab group (114 events in 195 patients); the 2-year rates of progression-free survival were 84.9% and 36.3%, respectively (hazard ratio for progression or death, 0.17; 95% confidence interval [CI], 0.11 to 0.25; P<0.001 by the stratified log-rank test). The benefit was maintained across all clinical and biologic subgroups, including the subgroup of patients with chromosome 17p deletion; the 2-year rate of progression-free survival among patients with chromosome 17p deletion was 81.5% in the venetoclax-rituximab group versus 27.8% in the bendamustine-rituximab group (hazard ratio, 0.13; 95% CI, 0.05 to 0.29), and the 2-year rate among those without chromosome 17p deletion was 85.9% versus 41.0% (hazard ratio, 0.19; 95% CI, 0.12 to 0.32). The benefit of venetoclax plus rituximab over bendamustine plus rituximab was confirmed by an independent review committee assessment of progression-free survival and other secondary efficacy end points. The rate of grade 3 or 4 neutropenia was higher in the venetoclax-rituximab group than in the bendamustine-rituximab group, but the rates of grade 3 or 4 febrile neutropenia and infections or infestations were lower with venetoclax than with bendamustine. The rate of grade 3 or 4 tumor lysis syndrome in the venetoclax-rituximab group was 3.1% (6 of 194 patients).RESULTSAfter a median follow-up period of 23.8 months, the rate of investigator-assessed progression-free survival was significantly higher in the venetoclax-rituximab group (32 events of progression or death in 194 patients) than in the bendamustine-rituximab group (114 events in 195 patients); the 2-year rates of progression-free survival were 84.9% and 36.3%, respectively (hazard ratio for progression or death, 0.17; 95% confidence interval [CI], 0.11 to 0.25; P<0.001 by the stratified log-rank test). The benefit was maintained across all clinical and biologic subgroups, including the subgroup of patients with chromosome 17p deletion; the 2-year rate of progression-free survival among patients with chromosome 17p deletion was 81.5% in the venetoclax-rituximab group versus 27.8% in the bendamustine-rituximab group (hazard ratio, 0.13; 95% CI, 0.05 to 0.29), and the 2-year rate among those without chromosome 17p deletion was 85.9% versus 41.0% (hazard ratio, 0.19; 95% CI, 0.12 to 0.32). The benefit of venetoclax plus rituximab over bendamustine plus rituximab was confirmed by an independent review committee assessment of progression-free survival and other secondary efficacy end points. The rate of grade 3 or 4 neutropenia was higher in the venetoclax-rituximab group than in the bendamustine-rituximab group, but the rates of grade 3 or 4 febrile neutropenia and infections or infestations were lower with venetoclax than with bendamustine. The rate of grade 3 or 4 tumor lysis syndrome in the venetoclax-rituximab group was 3.1% (6 of 194 patients).Among patients with relapsed or refractory chronic lymphocytic leukemia, venetoclax plus rituximab resulted in significantly higher rates of progression-free survival than bendamustine plus rituximab. (Funded by Genentech and AbbVie; ClinicalTrials.gov number, NCT02005471 .).CONCLUSIONSAmong patients with relapsed or refractory chronic lymphocytic leukemia, venetoclax plus rituximab resulted in significantly higher rates of progression-free survival than bendamustine plus rituximab. (Funded by Genentech and AbbVie; ClinicalTrials.gov number, NCT02005471 .). In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in a higher 2-year rate of progression-free survival than bendamustine in combination with rituximab (85% vs. 36%). |
| Author | Kipps, Thomas J Assouline, Sarit D’Rozario, James Gerecitano, John Boyer, Michelle Robak, Tadeusz Mobasher, Mehrdad Cartron, Guillaume Punnoose, Elizabeth A Jaeger, Ulrich Hillmen, Peter De la Serna, Javier Owen, Carolyn Li, Yan Humerickhouse, Rod Kater, Arnon P Humphrey, Kathryn Eichhorst, Barbara Seymour, John F Montillo, Marco |
| Author_xml | – sequence: 1 givenname: John F surname: Seymour fullname: Seymour, John F organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 2 givenname: Thomas J surname: Kipps fullname: Kipps, Thomas J organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 3 givenname: Barbara surname: Eichhorst fullname: Eichhorst, Barbara organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 4 givenname: Peter surname: Hillmen fullname: Hillmen, Peter organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 5 givenname: James surname: D’Rozario fullname: D’Rozario, James organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 6 givenname: Sarit surname: Assouline fullname: Assouline, Sarit organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 7 givenname: Carolyn surname: Owen fullname: Owen, Carolyn organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 8 givenname: John surname: Gerecitano fullname: Gerecitano, John organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 9 givenname: Tadeusz surname: Robak fullname: Robak, Tadeusz organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 10 givenname: Javier surname: De la Serna fullname: De la Serna, Javier organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 11 givenname: Ulrich surname: Jaeger fullname: Jaeger, Ulrich organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 12 givenname: Guillaume surname: Cartron fullname: Cartron, Guillaume organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 13 givenname: Marco surname: Montillo fullname: Montillo, Marco organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 14 givenname: Rod surname: Humerickhouse fullname: Humerickhouse, Rod organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 15 givenname: Elizabeth A surname: Punnoose fullname: Punnoose, Elizabeth A organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 16 givenname: Yan surname: Li fullname: Li, Yan organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 17 givenname: Michelle surname: Boyer fullname: Boyer, Michelle organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 18 givenname: Kathryn surname: Humphrey fullname: Humphrey, Kathryn organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 19 givenname: Mehrdad surname: Mobasher fullname: Mobasher, Mehrdad organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) – sequence: 20 givenname: Arnon P surname: Kater fullname: Kater, Arnon P organization: From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) — all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) — both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne–Bonn, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds (P.H.), and F. Hoffmann–La Roche, Welwyn Garden City (M.B., K.H.) — both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) — all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29562156$$D View this record in MEDLINE/PubMed https://hal.science/hal-02348612$$DView record in HAL |
| BookMark | eNp10UtrGzEQAGBRUhrHzbHXslAK6WFTvfZ1NCZPnARCm6uQtSMsd1dyJG2Jb_kP-Yf5JZWxU0ggukiIb0ajmQO0Z50FhL4QfExwUf68Prm8cpJUhDVV-QGNSMFYzjku99AIY1rnvGrYPjoIYYnTIrz5hPZpU5SUFOUIXd2BhehUJx-eH59uTRweTC_nmbHZLXRyFaDNnE9n7aWKzq-z6cI7a1Q2W_erhVPruDnD8Ad6Iz-jj1p2AQ53-xj9Pj35NT3PZzdnF9PJLFe8wTFnpYKK6KJWbd3WnEusdCMxpdDMK6WYLipFWmAaU6VxI4nSKQ4o17yYMw5sjH5s8y5kJ1Y-VezXwkkjziczsbnDlPG6JPQvSfZoa1fe3Q8QouhNUNB10oIbgqCYVKmRNcGJfntDl27wNv0kKcpJqrDYqK87Ncx7aP-__9LUBNgWKO9C8KCFMlFG42z00nSCYLEZnXg1uhSVv4l6Sfye_771fR-EhWX_jvsHOeKlGw |
| CitedBy_id | crossref_primary_10_1007_s00109_021_02120_z crossref_primary_10_1038_s41419_020_03144_y crossref_primary_10_1111_bjh_16879 crossref_primary_10_1002_hon_2985 crossref_primary_10_1016_S1470_2045_22_00266_2 crossref_primary_10_1080_14656566_2021_1882421 crossref_primary_10_3389_fimmu_2021_705974 crossref_primary_10_1007_s11899_021_00637_1 crossref_primary_10_1038_s41408_021_00520_5 crossref_primary_10_1182_bloodadvances_2024013687 crossref_primary_10_1007_s11864_022_00974_0 crossref_primary_10_3390_cancers16112011 crossref_primary_10_1097_HS9_0000000000000175 crossref_primary_10_1002_ajh_26809 crossref_primary_10_1182_blood_2024028110 crossref_primary_10_1007_s11912_019_0778_2 crossref_primary_10_1182_bloodadvances_2022007812 crossref_primary_10_58931_cht_2023_2235 crossref_primary_10_1007_s11899_020_00563_8 crossref_primary_10_1182_bloodadvances_2022007938 crossref_primary_10_1007_s11864_020_0715_5 crossref_primary_10_1016_S1470_2045_22_00220_0 crossref_primary_10_1016_S1470_2045_21_00455_1 crossref_primary_10_1080_10428194_2019_1612063 crossref_primary_10_1158_1078_0432_CCR_18_4158 crossref_primary_10_1002_cpt_2005 crossref_primary_10_1016_j_clml_2020_10_012 crossref_primary_10_2147_CMAR_S267258 crossref_primary_10_1016_j_trecan_2020_11_008 crossref_primary_10_1024_1661_8157_a003230 crossref_primary_10_1007_s11899_020_00586_1 crossref_primary_10_1182_bloodadvances_2023011741 crossref_primary_10_1002_hem3_146 crossref_primary_10_1016_j_lfs_2022_121146 crossref_primary_10_1038_s41419_021_03971_7 crossref_primary_10_1016_j_clml_2024_10_015 crossref_primary_10_3390_cancers14010051 crossref_primary_10_3390_ijms20030667 crossref_primary_10_1007_s00277_022_04777_z crossref_primary_10_1200_JCO_21_01194 crossref_primary_10_1002_cnr2_1983 crossref_primary_10_1002_cnr2_1505 crossref_primary_10_1016_j_leukres_2020_106373 crossref_primary_10_3389_fonc_2021_780085 crossref_primary_10_1080_14656566_2019_1582643 crossref_primary_10_1080_17474086_2020_1775575 crossref_primary_10_5045_br_2020_S012 crossref_primary_10_3390_ijms241210374 crossref_primary_10_1007_s40262_019_00788_8 crossref_primary_10_3390_cancers17050799 crossref_primary_10_1182_blood_2019001750 crossref_primary_10_1182_blood_2020010484 crossref_primary_10_3390_ijms241713069 crossref_primary_10_1200_EDBK_238735 crossref_primary_10_1080_10428194_2018_1508674 crossref_primary_10_1182_blood_2019002841 crossref_primary_10_2217_fon_2022_0112 crossref_primary_10_1007_s11864_023_01103_1 crossref_primary_10_1177_0272989X21992297 crossref_primary_10_3389_fonc_2023_1112616 crossref_primary_10_1097_HS9_0000000000000197 crossref_primary_10_1080_10428194_2021_1986217 crossref_primary_10_3390_jpm11040249 crossref_primary_10_1182_blood_2020004922 crossref_primary_10_3390_ijms24065802 crossref_primary_10_1038_s41419_021_04334_y crossref_primary_10_2147_OTT_S189032 crossref_primary_10_54097_hset_v36i_5684 crossref_primary_10_1002_cncr_32353 crossref_primary_10_1080_14737167_2023_2200167 crossref_primary_10_21320_2500_2139_2021_14_4_466_476 crossref_primary_10_1007_s11596_021_2385_3 crossref_primary_10_1158_1078_0432_CCR_21_1237 crossref_primary_10_1177_20406207221116577 crossref_primary_10_1182_blood_2018_05_853564 crossref_primary_10_3892_or_2022_8325 crossref_primary_10_1016_j_leukres_2020_106390 crossref_primary_10_1007_s12254_021_00778_2 crossref_primary_10_36290_xon_2020_100 crossref_primary_10_1007_s40259_024_00688_9 crossref_primary_10_1007_s40266_019_00678_5 crossref_primary_10_1038_s41571_024_00956_1 crossref_primary_10_1182_blood_2022016040 crossref_primary_10_1038_s41375_022_01543_y crossref_primary_10_1182_bloodadvances_2023011964 crossref_primary_10_1080_10428194_2020_1755857 crossref_primary_10_3390_jof7121058 crossref_primary_10_1007_s11523_019_00673_1 crossref_primary_10_1080_17474086_2023_2271170 crossref_primary_10_1182_bloodadvances_2023010879 crossref_primary_10_1056_NEJMoa2300696 crossref_primary_10_3390_jcm10215104 crossref_primary_10_1200_JCO_20_00491 crossref_primary_10_1002_14651858_CD013474 crossref_primary_10_1038_s41419_020_2670_2 crossref_primary_10_58931_cht_2024_3255 crossref_primary_10_1182_bloodadvances_2021005083 crossref_primary_10_1007_s00277_021_04419_w crossref_primary_10_1080_13543784_2021_1924669 crossref_primary_10_1002_hon_2943 crossref_primary_10_1080_10428194_2024_2310144 crossref_primary_10_17650_1818_8346_2022_17_4_38_47 crossref_primary_10_1080_10428194_2022_2047963 crossref_primary_10_1016_j_canlet_2021_07_045 crossref_primary_10_2217_fon_2019_0844 crossref_primary_10_56875_2589_0646_1039 crossref_primary_10_1182_blood_2018_12_889113 crossref_primary_10_1002_hon_2826 crossref_primary_10_1016_S1470_2045_18_30861_1 crossref_primary_10_1182_bloodadvances_2019000180 crossref_primary_10_1007_s00277_024_05644_9 crossref_primary_10_1097_MD_0000000000024703 crossref_primary_10_1186_s13046_021_02157_5 crossref_primary_10_21294_1814_4861_2020_19_6_106_118 crossref_primary_10_1111_bjh_17929 crossref_primary_10_1200_OP_24_00417 crossref_primary_10_1182_blood_2023020195 crossref_primary_10_1182_bloodadvances_2023010693 crossref_primary_10_1182_blood_2020008194 crossref_primary_10_1016_j_bcp_2019_01_015 crossref_primary_10_1016_j_neo_2020_11_010 crossref_primary_10_1016_j_leukres_2018_10_008 crossref_primary_10_6004_jnccn_2022_7069 crossref_primary_10_1038_s41416_020_01205_9 crossref_primary_10_1016_S2352_3026_18_30196_0 crossref_primary_10_1080_10428194_2024_2323682 crossref_primary_10_1097_QCO_0000000000000611 crossref_primary_10_12677_ACM_2023_133544 crossref_primary_10_3390_cancers15235592 crossref_primary_10_1038_s41598_024_68431_6 crossref_primary_10_1080_14656566_2023_2218545 crossref_primary_10_1182_bloodadvances_2019001145 crossref_primary_10_12677_ACM_2022_127911 crossref_primary_10_1016_j_intimp_2023_111135 crossref_primary_10_1159_000533234 crossref_primary_10_3390_cancers16050980 crossref_primary_10_3390_ijms20061285 crossref_primary_10_1177_20406207221127550 crossref_primary_10_36290_xon_2023_067 crossref_primary_10_3390_cancers15041018 crossref_primary_10_4103_ijmpo_ijmpo_260_20 crossref_primary_10_1016_S2352_3026_19_30085_7 crossref_primary_10_3390_cancers12040894 crossref_primary_10_3324_haematol_2022_282628 crossref_primary_10_3389_fonc_2023_1143881 crossref_primary_10_36290_xon_2023_061 crossref_primary_10_1080_10428194_2019_1709835 crossref_primary_10_1177_10781552221084616 crossref_primary_10_1080_10428194_2022_2098291 crossref_primary_10_1097_CAD_0000000000001653 crossref_primary_10_1016_j_blre_2021_100824 crossref_primary_10_1200_JCO_19_01718 crossref_primary_10_1002_acg2_51 crossref_primary_10_3389_fonc_2019_01421 crossref_primary_10_3960_jslrt_23023 crossref_primary_10_3390_cancers15041015 crossref_primary_10_3389_fmolb_2023_1182925 crossref_primary_10_1177_2040620719844697 crossref_primary_10_1172_JCI132374 crossref_primary_10_1016_j_bulcan_2018_08_014 crossref_primary_10_3389_frhem_2023_1307661 crossref_primary_10_1182_blood_2019003722 crossref_primary_10_1200_GO_20_00012 crossref_primary_10_1155_2021_8831125 crossref_primary_10_2147_PGPM_S407940 crossref_primary_10_1038_s41375_018_0223_9 crossref_primary_10_36290_xon_2023_052 crossref_primary_10_1002_ptr_8157 crossref_primary_10_1016_j_mpmed_2021_02_006 crossref_primary_10_1182_blood_2020004856 crossref_primary_10_3389_fonc_2019_00443 crossref_primary_10_1182_bloodadvances_2022007728 crossref_primary_10_1016_j_clml_2021_11_009 crossref_primary_10_1182_blood_2018_08_870238 crossref_primary_10_1158_1078_0432_CCR_19_1900 crossref_primary_10_1182_bloodadvances_2020002183 crossref_primary_10_1111_bjh_15836 crossref_primary_10_3389_fonc_2019_00689 crossref_primary_10_3324_haematol_2020_261107 crossref_primary_10_36290_xon_2019_021 crossref_primary_10_1038_s41375_021_01241_1 crossref_primary_10_1182_blood_2021011365 crossref_primary_10_1177_2040620721989588 crossref_primary_10_4103_crst_crst_179_22 crossref_primary_10_1182_hematology_2024000571 crossref_primary_10_1016_S1470_2045_24_00260_2 crossref_primary_10_1080_10428194_2022_2053532 crossref_primary_10_1097_HS9_0000000000000202 crossref_primary_10_1007_s12254_018_0414_0 crossref_primary_10_1016_j_clml_2022_07_013 crossref_primary_10_1126_scitranslmed_abo6891 crossref_primary_10_1056_NEJMe1904362 crossref_primary_10_1080_10428194_2022_2148210 crossref_primary_10_2478_ahp_2019_0008 crossref_primary_10_1016_S2152_2650_21_01241_6 crossref_primary_10_1038_s41408_024_01001_1 crossref_primary_10_1016_j_bioorg_2025_108388 crossref_primary_10_1093_omcr_omac111 crossref_primary_10_1158_0008_5472_CAN_23_0295 crossref_primary_10_1182_bloodadvances_2021006348 crossref_primary_10_3324_haematol_2019_236000 crossref_primary_10_1016_j_bbmt_2019_11_008 crossref_primary_10_1016_j_tranon_2019_01_009 crossref_primary_10_1080_10428194_2019_1680840 crossref_primary_10_1002_ajh_25662 crossref_primary_10_3390_cancers13122974 crossref_primary_10_1186_s12885_022_10223_0 crossref_primary_10_3389_fonc_2020_597730 crossref_primary_10_1080_14737140_2021_1856660 crossref_primary_10_1016_j_ejmech_2024_116663 crossref_primary_10_1158_2767_9764_CRC_23_0350 crossref_primary_10_1016_j_clml_2021_09_012 crossref_primary_10_1159_000510768 crossref_primary_10_1016_j_ccell_2019_06_005 crossref_primary_10_1016_S1470_2045_19_30338_9 crossref_primary_10_1111_bjh_15802 crossref_primary_10_3390_ijms25105246 crossref_primary_10_3324_haematol_2022_281850 crossref_primary_10_1182_bloodadvances_2020001956 crossref_primary_10_3389_fonc_2023_1106579 crossref_primary_10_1002_hon_2929 crossref_primary_10_3390_cancers12020282 crossref_primary_10_1182_blood_2021012675 crossref_primary_10_35754_0234_5730_2023_68_1_70_79 crossref_primary_10_1007_s15004_019_6365_8 crossref_primary_10_1182_blood_2020008201 crossref_primary_10_1111_bjh_18075 crossref_primary_10_1002_ccr3_5735 crossref_primary_10_1182_asheducation_2018_1_242 crossref_primary_10_3389_fonc_2022_1055113 crossref_primary_10_1007_s00277_020_03991_x crossref_primary_10_1056_NEJMoa1900574 crossref_primary_10_1002_ccr3_2580 crossref_primary_10_1080_10428194_2023_2255326 crossref_primary_10_1182_asheducation_2018_1_248 crossref_primary_10_1182_blood_2018_02_791350 crossref_primary_10_1007_s13402_024_00945_7 crossref_primary_10_1093_jjco_hyab112 crossref_primary_10_1016_j_clml_2019_03_003 crossref_primary_10_1016_S1470_2045_24_00196_7 crossref_primary_10_18632_oncotarget_26146 crossref_primary_10_1007_s00761_019_00655_y crossref_primary_10_1038_s41375_022_01629_7 crossref_primary_10_1007_s11912_019_0819_x crossref_primary_10_3390_cancers14235787 crossref_primary_10_1007_s40258_023_00826_4 crossref_primary_10_1182_blood_2021013990 crossref_primary_10_1016_j_clml_2019_09_612 crossref_primary_10_1182_asheducation_2018_1_256 crossref_primary_10_1007_s00277_024_05638_7 crossref_primary_10_3324_haematol_2020_257048 crossref_primary_10_1002_ajh_25595 crossref_primary_10_1002_ajh_26683 crossref_primary_10_1002_ajh_26682 crossref_primary_10_1007_s10238_023_01244_5 crossref_primary_10_1111_bjh_15901 crossref_primary_10_1159_000531675 crossref_primary_10_1016_j_pharmthera_2021_108010 crossref_primary_10_1056_NEJMra1908213 crossref_primary_10_1007_s00277_021_04746_y crossref_primary_10_3960_jslrt_20014 crossref_primary_10_1080_14728222_2018_1522302 crossref_primary_10_1111_cbdd_14169 crossref_primary_10_1182_blood_2020007376 crossref_primary_10_1182_blood_2021012775 crossref_primary_10_1002_jha2_543 crossref_primary_10_1056_NEJMc1805135 crossref_primary_10_1080_10428194_2020_1861278 crossref_primary_10_1002_ajh_26444 crossref_primary_10_1111_imj_16207 crossref_primary_10_1016_j_jtct_2021_10_005 crossref_primary_10_1080_17474086_2020_1796620 crossref_primary_10_1182_bloodadvances_2022009517 crossref_primary_10_1080_17474086_2019_1597703 crossref_primary_10_1186_s12943_022_01516_w crossref_primary_10_1002_jha2_427 crossref_primary_10_1007_s15004_024_0644_8 crossref_primary_10_1136_esmoopen_2019_000611 crossref_primary_10_1111_cts_13807 crossref_primary_10_1007_s12185_020_03024_3 crossref_primary_10_1155_2022_7451395 crossref_primary_10_1007_s12672_024_01161_3 crossref_primary_10_1038_s41571_020_0341_y crossref_primary_10_2147_PPA_S289139 crossref_primary_10_1016_j_leukres_2023_107372 crossref_primary_10_1182_bloodadvances_2018019422 crossref_primary_10_3390_jcm12051772 crossref_primary_10_1080_21678707_2020_1804860 crossref_primary_10_1016_j_yao_2021_02_020 crossref_primary_10_1080_16078454_2023_2237790 crossref_primary_10_1038_s41409_024_02256_9 crossref_primary_10_1097_PPO_0000000000000417 crossref_primary_10_3960_jslrt_20002 crossref_primary_10_1016_j_csbj_2024_10_017 crossref_primary_10_1097_PPO_0000000000000537 crossref_primary_10_1038_s41420_021_00505_0 crossref_primary_10_1177_2040620719891356 crossref_primary_10_1097_PPO_0000000000000413 crossref_primary_10_1200_JCO_20_02685 crossref_primary_10_1177_20406207241308771 crossref_primary_10_1016_j_clml_2023_02_001 crossref_primary_10_3390_curroncol30050339 crossref_primary_10_1007_s11864_021_00862_z crossref_primary_10_3389_fonc_2018_00636 crossref_primary_10_1182_blood_2018_11_880526 crossref_primary_10_3390_ijms231810957 crossref_primary_10_1016_j_clml_2019_05_013 crossref_primary_10_1182_hematology_2021000234 crossref_primary_10_1001_jama_2023_1946 crossref_primary_10_1080_10428194_2022_2123223 crossref_primary_10_3390_cancers17020268 crossref_primary_10_1186_s12935_020_01614_z crossref_primary_10_1080_10428194_2022_2043302 crossref_primary_10_20517_cdr_2023_97 crossref_primary_10_1002_hem3_70015 crossref_primary_10_1007_s11912_020_0893_0 crossref_primary_10_1016_j_clml_2023_01_009 crossref_primary_10_3960_jslrt_20036 crossref_primary_10_1182_blood_2020009578 crossref_primary_10_1159_000517067 crossref_primary_10_3390_cancers14010022 crossref_primary_10_1038_s41375_019_0597_3 crossref_primary_10_1038_s41408_021_00477_5 crossref_primary_10_3390_cancers12040938 crossref_primary_10_2147_CMAR_S283903 crossref_primary_10_1038_s41420_022_01093_3 crossref_primary_10_1002_ajh_27639 crossref_primary_10_1016_S2352_3026_24_00034_6 crossref_primary_10_1080_14737140_2023_2288899 crossref_primary_10_1182_blood_2018_01_785998 crossref_primary_10_1016_j_jaccao_2023_09_002 crossref_primary_10_1158_1078_0432_CCR_19_3815 crossref_primary_10_1182_hematology_2021000232 crossref_primary_10_1038_s41408_018_0131_2 crossref_primary_10_1056_NEJMoa1812836 crossref_primary_10_1556_2068_2021_54_3_4 crossref_primary_10_1097_HS9_0000000000000287 crossref_primary_10_1158_1078_0432_CCR_22_0433 crossref_primary_10_1007_s11899_022_00661_9 crossref_primary_10_1177_20406207221101697 crossref_primary_10_36290_xon_2024_018 crossref_primary_10_1182_blood_2021011895 crossref_primary_10_1182_hematology_2023000441 crossref_primary_10_3389_fonc_2023_1130617 crossref_primary_10_3390_cancers15153859 crossref_primary_10_1111_ejh_13273 crossref_primary_10_1080_14740338_2020_1802424 crossref_primary_10_1111_ejh_13396 crossref_primary_10_1016_j_ccell_2018_11_004 crossref_primary_10_1021_acsbiomaterials_3c01480 crossref_primary_10_1007_s11899_021_00652_2 crossref_primary_10_1038_s41375_022_01604_2 crossref_primary_10_1200_JCO_18_01580 crossref_primary_10_1007_s11899_019_00511_1 crossref_primary_10_1080_10428194_2025_2466101 crossref_primary_10_1007_s11899_018_0484_4 crossref_primary_10_1182_blood_2019004205 crossref_primary_10_1182_hematology_2020000120 crossref_primary_10_3390_nano10020276 crossref_primary_10_1016_S2152_2650_21_01218_0 crossref_primary_10_2174_1574892818666230117151757 crossref_primary_10_1002_jha2_227 crossref_primary_10_1002_ajh_26367 crossref_primary_10_1200_EDBK_320117 crossref_primary_10_3324_haematol_2023_284353 crossref_primary_10_1182_bloodadvances_2021006520 crossref_primary_10_1016_S1470_2045_18_30442_X crossref_primary_10_1016_S2352_3026_19_30253_4 crossref_primary_10_1007_s11899_023_00711_w crossref_primary_10_1038_s41467_023_37648_w crossref_primary_10_1016_S2152_2650_20_30472_9 crossref_primary_10_1038_s41598_024_64398_6 crossref_primary_10_1093_annonc_mdz053 crossref_primary_10_1097_HS9_0000000000000729 crossref_primary_10_1186_s40164_022_00283_0 crossref_primary_10_1016_j_molcel_2023_02_021 crossref_primary_10_1177_10781552221103820 crossref_primary_10_1038_s41375_022_01758_z crossref_primary_10_1186_s13148_022_01306_7 crossref_primary_10_1016_j_blre_2024_101195 crossref_primary_10_1080_10428194_2020_1734594 crossref_primary_10_1002_ajh_25261 crossref_primary_10_1016_j_annemergmed_2019_07_015 crossref_primary_10_1182_blood_2023022730 crossref_primary_10_1038_s41571_018_0159_z crossref_primary_10_1002_hem3_70004 crossref_primary_10_1200_OP_23_00630 crossref_primary_10_1159_000509934 crossref_primary_10_1007_s00277_020_03911_z crossref_primary_10_1182_blood_2021011993 crossref_primary_10_1016_j_clml_2024_05_009 crossref_primary_10_1080_10428194_2020_1768384 crossref_primary_10_1001_jamaoncol_2019_0167 crossref_primary_10_1097_CCO_0000000000000585 crossref_primary_10_1186_s13045_020_01018_6 crossref_primary_10_1002_cyto_b_22116 crossref_primary_10_1016_j_tcb_2019_09_001 crossref_primary_10_1177_0272989X20973201 crossref_primary_10_3390_curroncol28010037 crossref_primary_10_1080_10428194_2020_1761964 crossref_primary_10_1111_ejh_13928 crossref_primary_10_1016_j_semcancer_2022_01_009 crossref_primary_10_1007_s40265_021_01657_0 crossref_primary_10_1182_blood_2019001077 crossref_primary_10_1016_j_clml_2023_03_010 crossref_primary_10_1007_s12254_018_0466_1 crossref_primary_10_1097_PPO_0000000000000406 crossref_primary_10_1080_14737140_2020_1829482 crossref_primary_10_1182_bloodadvances_2022007364 crossref_primary_10_1002_ajh_27437 crossref_primary_10_1097_PPO_0000000000000407 crossref_primary_10_1182_blood_2020006785 crossref_primary_10_1021_acs_jmedchem_1c00940 crossref_primary_10_3389_fimmu_2023_1062376 crossref_primary_10_1097_PPO_0000000000000530 crossref_primary_10_1097_PPO_0000000000000411 crossref_primary_10_1182_blood_2020008608 crossref_primary_10_26559_mersinsbd_962931 crossref_primary_10_1097_PPO_0000000000000410 crossref_primary_10_1097_PPO_0000000000000531 crossref_primary_10_1097_CCO_0000000000000791 crossref_primary_10_1097_HS9_0000000000000983 crossref_primary_10_1007_s00277_023_05304_4 crossref_primary_10_3390_cancers15071996 crossref_primary_10_3390_ijms252312569 crossref_primary_10_1182_blood_2019_01_896290 crossref_primary_10_1182_hematology_2020000154 crossref_primary_10_1186_s13045_022_01295_3 crossref_primary_10_3390_cancers16111996 crossref_primary_10_1182_bloodadvances_2022008221 crossref_primary_10_1002_ajh_27546 crossref_primary_10_1159_000516683 crossref_primary_10_3324_haematol_2019_241539 crossref_primary_10_3390_diagnostics11050853 crossref_primary_10_1038_s41571_019_0239_8 crossref_primary_10_1182_bloodadvances_2021005883 crossref_primary_10_1002_cncr_31931 crossref_primary_10_1182_blood_2018882555 crossref_primary_10_1080_10428194_2021_2008383 crossref_primary_10_1007_s00108_019_00706_x crossref_primary_10_1080_14740338_2025_2449987 crossref_primary_10_1080_17425255_2019_1606211 crossref_primary_10_1016_S2352_3026_18_30222_9 crossref_primary_10_1182_bloodadvances_2024013927 crossref_primary_10_1182_hematology_2020000168 crossref_primary_10_3390_jcm9092903 crossref_primary_10_3389_fonc_2020_562558 crossref_primary_10_1182_blood_2020008502 crossref_primary_10_3390_biomedicines13030741 crossref_primary_10_1016_j_annonc_2020_09_019 crossref_primary_10_1016_j_beha_2019_05_008 crossref_primary_10_3390_jcm8050737 crossref_primary_10_1200_JCO_19_03355 crossref_primary_10_3389_fimmu_2019_02455 crossref_primary_10_1016_j_cbpa_2019_07_001 crossref_primary_10_1080_17474086_2024_2410003 crossref_primary_10_1182_hematology_2020000160 crossref_primary_10_1182_blood_2024024510 crossref_primary_10_1182_blood_2024024631 crossref_primary_10_3390_cancers12102725 crossref_primary_10_1038_s41375_019_0388_x crossref_primary_10_2217_fon_2023_0574 crossref_primary_10_1016_j_ijantimicag_2019_06_025 crossref_primary_10_1093_jjco_hyab170 crossref_primary_10_1002_hon_3122 crossref_primary_10_1182_bloodadvances_2019000864 crossref_primary_10_1186_s13045_023_01469_7 crossref_primary_10_3390_cells9051287 crossref_primary_10_1016_S2352_3026_21_00307_0 crossref_primary_10_3390_cancers14194644 crossref_primary_10_3390_ijms24076298 crossref_primary_10_1038_s41392_023_01521_5 crossref_primary_10_1080_10428194_2019_1657575 crossref_primary_10_1080_10428194_2019_1660974 crossref_primary_10_1007_s11899_020_00580_7 crossref_primary_10_1007_s11912_023_01454_w crossref_primary_10_1016_j_critrevonc_2024_104408 crossref_primary_10_3390_cancers16244168 crossref_primary_10_3390_cancers13061336 crossref_primary_10_1080_14740338_2025_2471508 crossref_primary_10_1111_bjh_17475 crossref_primary_10_18553_jmcp_2022_22075 crossref_primary_10_3390_ijms241411335 crossref_primary_10_1002_ajh_27247 crossref_primary_10_1177_10781552221090869 crossref_primary_10_17925_OHR_2018_14_2_63 crossref_primary_10_1007_s11912_020_0874_3 crossref_primary_10_1016_j_bulcan_2018_07_008 crossref_primary_10_1056_NEJMoa1815281 crossref_primary_10_1002_cncr_33933 crossref_primary_10_1080_14656566_2018_1524874 crossref_primary_10_1136_bmjopen_2020_039168 crossref_primary_10_1182_blood_2018_11_846808 crossref_primary_10_1016_j_crbiot_2020_05_001 crossref_primary_10_3390_cells9030717 crossref_primary_10_1007_s10238_021_00739_3 crossref_primary_10_3389_fphar_2022_989830 crossref_primary_10_1111_bjh_18558 crossref_primary_10_1007_s00277_024_05923_5 crossref_primary_10_1016_S0140_6736_23_01052_8 crossref_primary_10_3390_cancers16244274 crossref_primary_10_1111_ijlh_13875 crossref_primary_10_3390_biom12121880 crossref_primary_10_2147_DDDT_S458927 crossref_primary_10_2174_0118715206320224240910054728 crossref_primary_10_1038_s41375_020_01009_z crossref_primary_10_1053_j_seminhematol_2024_01_015 crossref_primary_10_1080_10428194_2023_2181657 crossref_primary_10_1182_blood_2021010845 crossref_primary_10_1016_S2352_3026_18_30212_6 crossref_primary_10_1002_14651858_CD013474_pub2 crossref_primary_10_3390_cancers16183182 crossref_primary_10_1111_bjh_18661 crossref_primary_10_1200_OP_23_00770 crossref_primary_10_1007_s12308_022_00497_5 crossref_primary_10_1007_s11899_023_00700_z crossref_primary_10_1016_j_molmed_2019_06_009 crossref_primary_10_1053_j_seminhematol_2024_01_004 crossref_primary_10_1016_j_hoc_2019_03_006 crossref_primary_10_1053_j_seminhematol_2024_01_003 crossref_primary_10_1182_blood_2018_10_879429 crossref_primary_10_1080_10428194_2024_2331631 crossref_primary_10_1080_14712598_2018_1508444 crossref_primary_10_1182_blood_2022016927 crossref_primary_10_3892_ol_2024_14526 crossref_primary_10_1080_10428194_2024_2445688 crossref_primary_10_2217_fon_2020_0640 crossref_primary_10_1182_hematology_2020000085 crossref_primary_10_1016_j_bbcan_2021_188569 crossref_primary_10_1038_s41418_023_01153_w crossref_primary_10_1182_hematology_2020000086 crossref_primary_10_1111_bjh_17326 crossref_primary_10_1007_s00277_024_05676_1 crossref_primary_10_3390_cancers11111660 crossref_primary_10_1016_j_blre_2022_100930 crossref_primary_10_1182_hematology_2019000070 crossref_primary_10_1080_10428194_2021_1876863 crossref_primary_10_1182_blood_2018_08_870808 crossref_primary_10_3324_haematol_2020_266486 crossref_primary_10_1007_s40265_019_01163_4 crossref_primary_10_1016_S0140_6736_24_00595_6 crossref_primary_10_3960_jslrt_24014 crossref_primary_10_1002_ijc_34377 crossref_primary_10_1080_14656566_2024_2398603 crossref_primary_10_1159_000500164 crossref_primary_10_1080_13543784_2020_1783239 crossref_primary_10_1080_14712598_2024_2413365 crossref_primary_10_1111_eci_13421 crossref_primary_10_1007_s11912_022_01261_9 crossref_primary_10_1080_10428194_2021_1964020 crossref_primary_10_1111_bjh_16345 crossref_primary_10_1007_s12185_020_02867_0 crossref_primary_10_1111_bjh_19613 crossref_primary_10_1002_jha2_1042 crossref_primary_10_1016_S2152_2650_21_01203_9 crossref_primary_10_1182_blood_2024026685 crossref_primary_10_1080_14728214_2020_1803829 crossref_primary_10_3390_cancers13102468 crossref_primary_10_1002_jha2_177 crossref_primary_10_1038_s41375_023_01901_4 crossref_primary_10_1158_2159_8290_CD_18_1119 crossref_primary_10_1200_JCO_18_01600 crossref_primary_10_1016_j_clml_2024_07_005 crossref_primary_10_1056_NEJMra2027424 crossref_primary_10_7889_tct_21_017 crossref_primary_10_3390_cancers14102537 crossref_primary_10_1007_s00210_025_03911_8 crossref_primary_10_1007_s15004_019_6658_y crossref_primary_10_1080_14712598_2022_2145881 crossref_primary_10_3390_cancers13102310 crossref_primary_10_1016_S2352_3026_22_00034_5 crossref_primary_10_3390_cancers12113353 crossref_primary_10_1056_NEJMoa2213093 crossref_primary_10_3390_cancers12030642 crossref_primary_10_1177_10781552251324522 crossref_primary_10_1016_j_bneo_2024_100047 crossref_primary_10_1080_10428194_2018_1543882 crossref_primary_10_1080_14728222_2020_1832465 crossref_primary_10_1038_s41408_022_00756_9 crossref_primary_10_1002_1878_0261_13364 crossref_primary_10_1177_17588359241285988 crossref_primary_10_1007_s12185_024_03832_x crossref_primary_10_1038_s41408_022_00721_6 crossref_primary_10_1182_bloodadvances_2023011327 crossref_primary_10_1007_s10238_021_00784_y crossref_primary_10_1111_bjh_16442 crossref_primary_10_1080_17474086_2018_1495557 crossref_primary_10_2144_fsoa_2019_0064 crossref_primary_10_1038_s41418_020_00692_w crossref_primary_10_1038_s41420_020_00348_1 crossref_primary_10_1182_blood_2021015014 crossref_primary_10_1007_s10198_021_01398_7 crossref_primary_10_3324_haematol_2020_255448 crossref_primary_10_1111_bjh_18738 crossref_primary_10_1182_blood_2019004767 crossref_primary_10_1016_j_hoc_2021_03_005 crossref_primary_10_1016_j_hoc_2021_03_004 crossref_primary_10_1177_10781552221082295 crossref_primary_10_1042_BST20210749 crossref_primary_10_1111_bjh_15460 crossref_primary_10_3390_jcm10102064 crossref_primary_10_1097_HS9_0000000000000801 crossref_primary_10_1080_17474086_2018_1480364 crossref_primary_10_1097_CAD_0000000000001350 crossref_primary_10_1016_j_medcle_2024_10_012 crossref_primary_10_1080_10428194_2020_1802454 crossref_primary_10_1134_S0006297920100090 crossref_primary_10_3390_cells10010098 crossref_primary_10_1002_hon_2794 crossref_primary_10_1080_17474086_2019_1575130 crossref_primary_10_1042_BST20210750 crossref_primary_10_1186_s13046_021_02115_1 crossref_primary_10_1200_JCO_20_00948 crossref_primary_10_18632_oncotarget_26964 crossref_primary_10_1080_10408363_2019_1600468 crossref_primary_10_1158_2159_8290_CD_18_1151 crossref_primary_10_1016_j_pathol_2021_04_008 crossref_primary_10_1038_s41408_022_00720_7 crossref_primary_10_1182_blood_2018_08_869503 crossref_primary_10_1080_10428194_2024_2412289 crossref_primary_10_1111_1751_2980_12848 crossref_primary_10_1007_s11864_022_00953_5 crossref_primary_10_1182_blood_2024024341 crossref_primary_10_3390_cancers13061292 crossref_primary_10_1080_1120009X_2022_2125749 crossref_primary_10_1016_j_ejphar_2023_175588 crossref_primary_10_1186_s40001_024_01822_7 crossref_primary_10_1001_jamanetworkopen_2024_14425 crossref_primary_10_1177_17588359241263710 crossref_primary_10_3390_life12020283 crossref_primary_10_1016_j_medcli_2024_10_018 crossref_primary_10_1177_1078155219853030 crossref_primary_10_1016_j_hoc_2021_03_007 crossref_primary_10_1016_j_hoc_2021_03_008 crossref_primary_10_1007_s40261_022_01172_4 crossref_primary_10_1016_j_clml_2022_04_017 crossref_primary_10_1080_03007995_2021_1929894 crossref_primary_10_1080_14712598_2020_1734557 crossref_primary_10_1111_bjh_18715 crossref_primary_10_1007_s15004_019_6382_7 crossref_primary_10_1007_s44313_024_00038_2 crossref_primary_10_1080_10428194_2019_1622098 crossref_primary_10_1016_j_ejim_2018_02_001 crossref_primary_10_3390_cancers13133134 crossref_primary_10_1002_1878_0261_13309 crossref_primary_10_1007_s00432_021_03593_8 crossref_primary_10_1038_s41571_018_0037_8 crossref_primary_10_1182_bloodadvances_2019000360 crossref_primary_10_3390_cancers16203483 crossref_primary_10_1016_j_canlet_2019_05_009 crossref_primary_10_6004_jnccn_2022_0031 crossref_primary_10_2147_OTT_S443924 crossref_primary_10_3390_jcm10245845 crossref_primary_10_1080_10428194_2019_1691193 crossref_primary_10_1007_s11010_020_03796_6 crossref_primary_10_1080_10428194_2024_2301738 crossref_primary_10_1080_14737140_2024_2398483 crossref_primary_10_1007_s12254_021_00735_z crossref_primary_10_1080_10428194_2022_2084731 crossref_primary_10_1182_blood_2019_03_901090 crossref_primary_10_1126_scitranslmed_aat3887 crossref_primary_10_1080_10428194_2021_1910684 crossref_primary_10_58931_cht_2024_3s01_244 crossref_primary_10_1016_j_clml_2022_04_007 crossref_primary_10_2217_ijh_2020_0010 crossref_primary_10_3324_haematol_2022_282116 crossref_primary_10_1007_s12325_022_02170_w crossref_primary_10_1111_bjh_15791 crossref_primary_10_1111_cts_13450 crossref_primary_10_1080_10428194_2024_2374041 crossref_primary_10_1007_s11864_023_01112_0 crossref_primary_10_1007_s00277_020_04094_3 crossref_primary_10_1080_17512433_2021_2008239 crossref_primary_10_3390_ph17040484 crossref_primary_10_3390_cancers12030574 crossref_primary_10_1080_10428194_2025_2482132 crossref_primary_10_1080_17474086_2020_1797482 crossref_primary_10_1002_hon_2583 crossref_primary_10_1182_bloodadvances_2019001205 crossref_primary_10_1182_bloodadvances_2019001204 crossref_primary_10_1080_10428194_2024_2392813 crossref_primary_10_4044_joma_133_120 |
| Cites_doi | 10.1038/leu.2012.25 10.1200/JCO.2009.26.4556 10.1016/S1470-2045(17)30012-8 10.1002/cncr.25853 10.1172/JCI28281 10.1056/NEJMoa1315226 10.1016/S1470-2045(16)30019-5 10.1073/pnas.0506654102 10.1182/blood.V126.23.720.720 10.1001/jama.2013.281053 10.1126/scitranslmed.aaa4642 10.1093/annonc/mdv303 10.3109/10428194.2015.1011641 10.1200/JCO.2011.36.9348 10.1016/S0378-3758(01)00077-5 10.1016/S0140-6736(10)61381-5 10.1016/S1470-2045(16)30671-4 10.3816/CLML.2010.n.002 10.1016/S1470-2045(14)70335-3 10.1016/S1470-2045(15)00465-9 10.1056/NEJMoa1400376 10.1182/blood-2016-05-714162 10.1182/blood-2007-06-093906 10.1182/blood-2016-01-688796 10.1200/JCO.2016.34.15_suppl.7528 10.1182/blood-2002-04-1258 10.1056/NEJMoa1509981 10.1016/j.trecan.2016.07.001 10.1038/nm.3048 10.1056/NEJM200012283432602 10.1056/NEJMoa1513257 10.1200/JCO.2010.33.8061 |
| ContentType | Journal Article |
| Copyright | Copyright © 2018 Massachusetts Medical Society. All rights reserved. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: Copyright © 2018 Massachusetts Medical Society. All rights reserved. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7RV 7X7 7XB 8AO 8C1 8FE 8FH 8FI ABUWG AFKRA AN0 AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K0Y LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 1XC |
| DOI | 10.1056/NEJMoa1713976 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep SciTech Premium Collection New England Journal of Medicine ProQuest Biological Science Collection Consumer Health Database Health Management Database Medical Database Psychology Database Research Library Science Database Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic Hyper Article en Ligne (HAL) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials elibrary ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing New England Journal of Medicine ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest One Psychology MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1533-4406 |
| EndPage | 1120 |
| ExternalDocumentID | oai_HAL_hal_02348612v1 29562156 10_1056_NEJMoa1713976 NJ201803223781208 |
| Genre | Original Article Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Australia United States--US California |
| GeographicLocations_xml | – name: United States--US – name: California – name: Australia |
| GroupedDBID | - 0R 0WA 123 186 1VV 29N 2KS 2WC 34G 39C 3V. 4 4.4 53G 55 5RE 7FN 7RV 7X7 85S 8AO 8C1 8FE 8FH 8FI AACLI AAEJM AAIKC AALRV AAPBV AAQQT AARDX AAWTL ABACO ABEHJ ABFLS ABIVO ABOCM ABPPZ ABPTK ABQIJ ABUWG ABWJO ACGFS ACGOD ACJLH ACNCT ACPRK ACRZS ADBBV ADBIT ADCBC ADRHT AENEX AETEA AFFNX AFHKK AFKRA AGFXO AGNAY AHMBA AJJEV AJVPN ALMA_UNASSIGNED_HOLDINGS AN0 AQUVI AZQEC BBAFP BBNVY BCU BENPR BES BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BVXVI C45 CJ0 CO CS3 DCD DU5 DWQXO DZ EBS EJD ET EX3 F5P FD8 FM. FYUFA GJ GNUQQ GUQSH H13 HCIFZ HZ I4R IH2 K-O KM KOO L7B LK8 M0R M0T M1P M2M M2O M2P M7P MVM N9A NAPCQ NEJ O9- OK1 OMK OVD P-O P-S P2P PADUT PCD PQEST PQQKQ PQUKI PRINS PROAC PSQYO QJJ RHI RWL RXW S10 S6N SJFOW SJN TAE TAF TEORI TN5 TUQ TWZ UCV UKR UMD VQA W2G WH7 WOQ WOW X X7M XJT XYN XZL YCJ YNT YRY YZZ ZA5 ZHY ZR0 --- -DZ -ET -~X .-4 .55 .CO .GJ 0R~ 36B AAMNW AAQOH AAYXX ABBLC ABCQX ABDQB ABJNI ACKOT ACPFK ADUKH AERZD AFOSN AGHSJ ALIPV BYPQX CCPQU CITATION HF~ HMCUK HZ~ N4W PHGZM PHGZT PSYQQ UKHRP YFH YR2 YR5 YYP ZCA ZVN ~KM CGR CUY CVF ECM EIF NPM R.3 UIG VXZ YIF YIN Z5M 7XB BEC K0Y MBDVC PJZUB PKEHL PPXIY PQGLB Q9U 7X8 1CY 1KJ 1XC 3O- 41~ 6TJ 8WZ 9M8 A6W AAUTI AAYOK ABDPE ABEFU ACPVT ACTDY AFFDN AJUXI D0S FA8 J5H LPU MQT NHB OHT QZG SKT UBX UMC UQL WHG XOL YHZ YQI YQJ YYQ ZGI ZKB ZXP |
| ID | FETCH-LOGICAL-c490t-36ce71f58cd8d844a0cf9a022e9b7cc3f57c1de3f02cf09a1cf490e24f45b34e3 |
| IEDL.DBID | 7X7 |
| ISSN | 0028-4793 1533-4406 |
| IngestDate | Fri May 09 12:22:55 EDT 2025 Thu Jul 10 23:45:00 EDT 2025 Sat Aug 23 12:22:17 EDT 2025 Wed Feb 19 02:35:22 EST 2025 Thu Apr 24 22:53:28 EDT 2025 Tue Jul 01 01:43:23 EDT 2025 Tue Dec 21 14:39:00 EST 2021 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | Recurrence Lymphocytic Humans Middle Aged Leukemia Male Residual 80 and over Young Adult B-Cell Female Adult Tumor Lysis Syndrome Heterocyclic Drug Resistance Neutropenia Kaplan-Meier Estimate Rituximab Antineoplastic Combined Chemotherapy Protocols Neoplasm Disease-Free Survival Chronic Bendamustine Hydrochloride Sulfonamides Aged Bridged Bicyclo Compounds |
| Language | English |
| License | http://www.nejmgroup.org/legal/terms-of-use.htm Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c490t-36ce71f58cd8d844a0cf9a022e9b7cc3f57c1de3f02cf09a1cf490e24f45b34e3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0003-0659-9635 0000-0002-6336-0981 |
| OpenAccessLink | https://www.nejm.org/doi/pdf/10.1056/NEJMoa1713976?articleTools=true |
| PMID | 29562156 |
| PQID | 2024102250 |
| PQPubID | 40644 |
| PageCount | 14 |
| ParticipantIDs | hal_primary_oai_HAL_hal_02348612v1 proquest_miscellaneous_2017056810 proquest_journals_2024102250 pubmed_primary_29562156 crossref_citationtrail_10_1056_NEJMoa1713976 crossref_primary_10_1056_NEJMoa1713976 mms_nejm_10_1056_NEJMoa1713976 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-03-22 |
| PublicationDateYYYYMMDD | 2018-03-22 |
| PublicationDate_xml | – month: 03 year: 2018 text: 2018-03-22 day: 22 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Boston |
| PublicationTitle | The New England journal of medicine |
| PublicationTitleAlternate | N Engl J Med |
| PublicationYear | 2018 |
| Publisher | Massachusetts Medical Society |
| Publisher_xml | – name: Massachusetts Medical Society |
| References | Roberts, AW, Davids, MS, Pagel, JM (r016) 2016; 374 Pospisilova, S, Gonzalez, D, Malcikova, J (r033) 2012; 26 Robak, T, Dmoszynska, A, Solal-Céligny, P (r037) 2010; 28 Dimier, N, Delmar, P, Ward, C, Morariu-Zamfir, R, Fingerle-Rowson, G (r025) 2015; 126 Del Gaizo Moore, V, Brown, JR, Certo, M, Love, TM, Novina, CD, Letai, A (r011) 2007; 117 r023 Burger, JA, Keating, MJ, Wierda, WG (r002) 2014; 15 Robertson, LE, Plunkett, W, McConnell, K, Keating, MJ, McDonnell, TJ (r012) 1996; 10 Byrd, JC, Harrington, B, O’Brien, S (r004) 2016; 374 r036 Westfall, PH, Krishen, A (r035) 2001; 99 Cory, S, Roberts, AW, Colman, PM, Adams, JM (r009) 2016; 2 Hallek, M, Cheson, BD, Catovsky, D (r032) 2008; 111 Hallek, M, Fischer, K, Fingerle-Rowson, G (r018) 2010; 376 Döhner, H, Stilgenbauer, S, Benner, A (r034) 2000; 343 Stilgenbauer, S, Eichhorst, B, Schetelig, J (r015) 2016; 17 Kwok, M, Rawstron, AC, Varghese, A (r022) 2016; 128 Cheson, BD, Wendtner, CM, Pieper, A (r027) 2010; 10 (r030) 1997; 48 Thijssen, R, Slinger, E, Weller, K (r020) 2015; 100 Chanan-Khan, A, Cramer, P, Demirkan, F (r007) 2016; 17 Fischer, K, Cramer, P, Busch, R (r001) 2011; 29 Tam, CS, Stilgenbauer, S (r008) 2015; 56 Anderson, MA, Deng, J, Seymour, JF (r014) 2016; 127 Davids, M, Gerecitano, J, Potluri, J (r039) 2016; 34 Furman, RR, Sharman, JP, Coutre, SE (r005) 2014; 370 (r031) 2013; 310 Leverson, JD, Phillips, DC, Mitten, MJ (r038) 2015; 7 Seymour, JF, Ma, S, Brander, DM (r021) 2017; 18 Souers, AJ, Leverson, JD, Boghaert, ER (r013) 2013; 19 r029 Zelenetz, AD, Barrientos, JC, Brown, JR (r006) 2017; 18 Ferrajoli, A, Keating, MJ, O’Brien, S, Cortes, J, Thomas, DA (r019) 2011; 117 Eichhorst, B, Robak, T, Montserrat, E (r028) 2015; 26 r026 Cimmino, A, Calin, GA, Fabbri, M (r010) 2005; 102 Byrd, JC, Peterson, BL, Morrison, VA (r017) 2003; 101 Böttcher, S, Ritgen, M, Fischer, K (r024) 2012; 30 Byrd, JC, Brown, JR, O’Brien, S (r003) 2014; 371 e_1_3_5_28_2 e_1_3_5_27_2 e_1_3_5_26_2 e_1_3_5_25_2 e_1_3_5_23_2 e_1_3_5_22_2 Kovacs G (e_1_3_5_24_2) 2016 e_1_3_5_29_2 e_1_3_5_2_2 e_1_3_5_40_2 e_1_3_5_8_2 e_1_3_5_20_2 e_1_3_5_7_2 e_1_3_5_9_2 e_1_3_5_4_2 e_1_3_5_3_2 e_1_3_5_6_2 e_1_3_5_5_2 e_1_3_5_17_2 e_1_3_5_39_2 e_1_3_5_16_2 e_1_3_5_38_2 e_1_3_5_15_2 e_1_3_5_14_2 e_1_3_5_36_2 e_1_3_5_12_2 e_1_3_5_35_2 e_1_3_5_34_2 e_1_3_5_10_2 e_1_3_5_33_2 e_1_3_5_11_2 e_1_3_5_32_2 e_1_3_5_19_2 Shanafelt TD (e_1_3_5_37_2) 2009 e_1_3_5_18_2 Thijssen R (e_1_3_5_21_2) 2015; 100 e_1_3_5_30_2 (e_1_3_5_31_2) 1997; 48 Robertson LE (e_1_3_5_13_2) 1996; 10 29847898 - N Engl J Med. 2018 May 31;378(22):2142-3 29651129 - Nat Rev Clin Oncol. 2018 Jun;15(6):344-345 29847897 - N Engl J Med. 2018 May 31;378(22):2141-2 |
| References_xml | – volume: 7 start-page: 279ra40 year: 2015 end-page: 279ra40 ident: r038 article-title: Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. publication-title: Sci Transl Med – volume: 127 start-page: 3215 year: 2016 end-page: 3224 ident: r014 article-title: The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. publication-title: Blood – volume: 19 start-page: 202 year: 2013 end-page: 208 ident: r013 article-title: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. publication-title: Nat Med – volume: 29 start-page: 3559 year: 2011 end-page: 3566 ident: r001 article-title: Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. publication-title: J Clin Oncol – volume: 370 start-page: 997 year: 2014 end-page: 1007 ident: r005 article-title: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. publication-title: N Engl J Med – volume: 10 start-page: 456 year: 1996 end-page: 459 ident: r012 article-title: Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. publication-title: Leukemia – volume: 343 start-page: 1910 year: 2000 end-page: 1916 ident: r034 article-title: Genomic aberrations and survival in chronic lymphocytic leukemia. publication-title: N Engl J Med – volume: 10 start-page: 21 year: 2010 end-page: 27 ident: r027 article-title: Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. publication-title: Clin Lymphoma Myeloma Leuk – volume: 101 start-page: 6 year: 2003 end-page: 14 ident: r017 article-title: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). publication-title: Blood – volume: 17 start-page: 768 year: 2016 end-page: 778 ident: r015 article-title: Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. publication-title: Lancet Oncol – volume: 30 start-page: 980 year: 2012 end-page: 988 ident: r024 article-title: Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. publication-title: J Clin Oncol – volume: 2 start-page: 443 year: 2016 end-page: 460 ident: r009 article-title: Targeting BCL-2-like proteins to kill cancer cells. publication-title: Trends Cancer – volume: 102 start-page: 13944 year: 2005 end-page: 13949 ident: r010 article-title: miR-15 and miR-16 Induce apoptosis by targeting BCL2. publication-title: Proc Natl Acad Sci U S A – volume: 17 start-page: 200 year: 2016 end-page: 211 ident: r007 article-title: Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. publication-title: Lancet Oncol – volume: 99 start-page: 25 year: 2001 end-page: 40 ident: r035 article-title: Optimally weighted, fixed sequence and gatekeeper multiple testing procedures. publication-title: J Stat Plan Inference – volume: 111 start-page: 5446 year: 2008 end-page: 5456 ident: r032 article-title: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. publication-title: Blood – volume: 374 start-page: 323 year: 2016 end-page: 332 ident: r004 article-title: Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. publication-title: N Engl J Med – volume: 126 start-page: 720 year: 2015 end-page: 720 ident: r025 article-title: Model for predicting effect of treatment on progression-free survival using minimal residual disease as a surrogate endpoint in chronic lymphocytic leukemia. publication-title: Blood – ident: r029 article-title: National Comprehensive Cancer Network. NCCN guidelines: chronic lymphocytic leukemia/small lymphocytic lymphoma. Version 2.2017. February 21, 2017 ( https://www.nccn.org/professionals/physician_gls/f_guidelines.asp ). – volume: 15 start-page: 1090 year: 2014 end-page: 1099 ident: r002 article-title: Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. publication-title: Lancet Oncol – start-page: 3758 end-page: 3765 ident: r023 – ident: r026 article-title: Hallek M. Presentation and discussion of revised iwCLL guidelines for the approach to a CLL patient. Presented at the XVII International Workshop on Chronic Lymphocytic Leukemia, New York, May 12–15, 2017. – volume: 48 start-page: 231 year: 1997 end-page: 234 ident: r030 article-title: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use. publication-title: Int Dig Health Legis – volume: 18 start-page: 297 year: 2017 end-page: 311 ident: r006 article-title: Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. publication-title: Lancet Oncol – volume: 56 start-page: 587 year: 2015 end-page: 593 ident: r008 article-title: How best to manage patients with chronic lymphocytic leukemia with 17p deletion and/or TP53 mutation? publication-title: Leuk Lymphoma – volume: 18 start-page: 230 year: 2017 end-page: 240 ident: r021 article-title: Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. publication-title: Lancet Oncol – volume: 100 start-page: e302 year: 2015 end-page: e306 ident: r020 article-title: Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. publication-title: Haematologica – volume: 376 start-page: 1164 year: 2010 end-page: 1174 ident: r018 article-title: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. publication-title: Lancet – volume: 34 start-page: 7528 year: 2016 end-page: 7528 ident: r039 article-title: Integrated safety analysis of venetoclax monotherapy in chronic lymphocytic leukemia (CLL). ;:Suppl publication-title: J Clin Oncol – volume: 117 start-page: 112 year: 2007 end-page: 121 ident: r011 article-title: Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. publication-title: J Clin Invest – start-page: 421 end-page: 429 ident: r036 – volume: 28 start-page: 1756 year: 2010 end-page: 1765 ident: r037 article-title: Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. publication-title: J Clin Oncol – volume: 374 start-page: 311 year: 2016 end-page: 322 ident: r016 article-title: Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. publication-title: N Engl J Med – volume: 26 start-page: v78 year: 2015 end-page: v84 ident: r028 article-title: Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ;:Suppl 5 publication-title: Ann Oncol – volume: 371 start-page: 213 year: 2014 end-page: 223 ident: r003 article-title: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. publication-title: N Engl J Med – volume: 128 start-page: 2770 year: 2016 end-page: 2773 ident: r022 article-title: Minimal residual disease is an independent predictor for 10-year survival in CLL. publication-title: Blood – volume: 310 start-page: 2191 year: 2013 end-page: 2194 ident: r031 article-title: World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. publication-title: JAMA ;World Medical Association – volume: 26 start-page: 1458 year: 2012 end-page: 1461 ident: r033 article-title: ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. publication-title: Leukemia – volume: 117 start-page: 3182 year: 2011 end-page: 3186 ident: r019 article-title: Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. publication-title: Cancer – ident: e_1_3_5_34_2 doi: 10.1038/leu.2012.25 – ident: e_1_3_5_38_2 doi: 10.1200/JCO.2009.26.4556 – ident: e_1_3_5_22_2 doi: 10.1016/S1470-2045(17)30012-8 – ident: e_1_3_5_20_2 doi: 10.1002/cncr.25853 – ident: e_1_3_5_12_2 doi: 10.1172/JCI28281 – ident: e_1_3_5_6_2 doi: 10.1056/NEJMoa1315226 – ident: e_1_3_5_16_2 doi: 10.1016/S1470-2045(16)30019-5 – ident: e_1_3_5_11_2 doi: 10.1073/pnas.0506654102 – ident: e_1_3_5_26_2 doi: 10.1182/blood.V126.23.720.720 – ident: e_1_3_5_32_2 doi: 10.1001/jama.2013.281053 – ident: e_1_3_5_39_2 doi: 10.1126/scitranslmed.aaa4642 – ident: e_1_3_5_29_2 doi: 10.1093/annonc/mdv303 – volume: 10 start-page: 456 year: 1996 ident: e_1_3_5_13_2 article-title: Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. publication-title: Leukemia – start-page: 421 volume-title: Hematol Am Soc Hematol Educ Program year: 2009 ident: e_1_3_5_37_2 – ident: e_1_3_5_30_2 – ident: e_1_3_5_9_2 doi: 10.3109/10428194.2015.1011641 – start-page: 3758 volume-title: J Clin Oncol year: 2016 ident: e_1_3_5_24_2 – ident: e_1_3_5_25_2 doi: 10.1200/JCO.2011.36.9348 – ident: e_1_3_5_36_2 doi: 10.1016/S0378-3758(01)00077-5 – ident: e_1_3_5_19_2 doi: 10.1016/S0140-6736(10)61381-5 – ident: e_1_3_5_7_2 doi: 10.1016/S1470-2045(16)30671-4 – ident: e_1_3_5_28_2 doi: 10.3816/CLML.2010.n.002 – ident: e_1_3_5_27_2 – ident: e_1_3_5_3_2 doi: 10.1016/S1470-2045(14)70335-3 – ident: e_1_3_5_8_2 doi: 10.1016/S1470-2045(15)00465-9 – ident: e_1_3_5_4_2 doi: 10.1056/NEJMoa1400376 – ident: e_1_3_5_23_2 doi: 10.1182/blood-2016-05-714162 – ident: e_1_3_5_33_2 doi: 10.1182/blood-2007-06-093906 – ident: e_1_3_5_15_2 doi: 10.1182/blood-2016-01-688796 – volume: 48 start-page: 231 year: 1997 ident: e_1_3_5_31_2 article-title: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use. publication-title: Int Dig Health Legis – ident: e_1_3_5_40_2 doi: 10.1200/JCO.2016.34.15_suppl.7528 – ident: e_1_3_5_18_2 doi: 10.1182/blood-2002-04-1258 – ident: e_1_3_5_5_2 doi: 10.1056/NEJMoa1509981 – ident: e_1_3_5_10_2 doi: 10.1016/j.trecan.2016.07.001 – ident: e_1_3_5_14_2 doi: 10.1038/nm.3048 – volume: 100 start-page: e302 issue: 8 year: 2015 ident: e_1_3_5_21_2 article-title: Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. publication-title: Haematologica – ident: e_1_3_5_35_2 doi: 10.1056/NEJM200012283432602 – ident: e_1_3_5_17_2 doi: 10.1056/NEJMoa1513257 – ident: e_1_3_5_2_2 doi: 10.1200/JCO.2010.33.8061 – reference: 29847898 - N Engl J Med. 2018 May 31;378(22):2142-3 – reference: 29651129 - Nat Rev Clin Oncol. 2018 Jun;15(6):344-345 – reference: 29847897 - N Engl J Med. 2018 May 31;378(22):2141-2 |
| SSID | ssj0000149 |
| Score | 2.69176 |
| Snippet | In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in... Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and that is central to the survival of chronic lymphocytic leukemia... BackgroundVenetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and that is central to the survival of chronic lymphocytic... BACKGROUND: Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and that is central to the survival of chronic lymphocytic... |
| SourceID | hal proquest pubmed crossref mms |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1107 |
| SubjectTerms | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bendamustine Hydrochloride - administration & dosage Bendamustine Hydrochloride - adverse effects Bone marrow Bridged Bicyclo Compounds, Heterocyclic - administration & dosage Bridged Bicyclo Compounds, Heterocyclic - adverse effects Cancer therapies Chemotherapy Chromosome 17 Chromosome deletion Chromosomes Chronic lymphocytic leukemia Clinical trials Clonal deletion Disease-Free Survival Drug dosages Drug Resistance, Neoplasm Evidence-based medicine Female Hematology Humans Immunotherapy Kaplan-Meier Estimate Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - mortality Life Sciences Lymphatic leukemia Lysis Male Middle Aged Monoclonal antibodies Neoplasm, Residual Neutropenia Neutropenia - chemically induced Oncology Patients Recurrence Response rates Rituximab Rituximab - administration & dosage Rituximab - adverse effects Sulfonamides - administration & dosage Sulfonamides - adverse effects Targeted cancer therapy Tumor Lysis Syndrome - etiology Young Adult |
| Title | Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia |
| URI | https://nejm.org/doi/full/10.1056/NEJMoa1713976 https://www.ncbi.nlm.nih.gov/pubmed/29562156 https://www.proquest.com/docview/2024102250 https://www.proquest.com/docview/2017056810 https://hal.science/hal-02348612 |
| Volume | 378 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED_RTUK8IDa-AlsVEOKJiCR2vp7QmDZVsE1oYqhvke2ctcKSlDZF63_PXeoW9tC9JFZysaI72_c7f_wO4J0W5NQISQdVEkoKUCIMtNBRkFTSVrk2Msv5NPL5RTq6kl_GydhNuM3dtsr1mNgP1FVreI6cg3TJ0UkSfpr-DjhrFK-uuhQaA9hl6jJu1dk4-48-ysFfN4PkODbJ53_kTPOtijIGQOkdnzS45h2Rg7qebwedvfM5fQKPHWr0j1Zm3oMH2OzDw3O3Lv4Uvv6gIatrzY26DS4n3eJ2UivtTxqf97pN51j57YzKdtZn11n6jhLXP1uSMVuz7LiMi19YT9QzuDo9-X48ClyahMDIIuwCkRrMIpvkpsqrXEoVGlsoUhUWOjNG2CQzUYXChrGxYaEiY-k7jKWViRYSxXPYadoGX4KPhqIXVaBRKUqh40JT9IYU9QhD9zzz4MNaUaVxHOKcyuKm7Neyk7S8o1cP3m_EpyvyjG2Cb0nrGxmmvB4dnZX8jDCFzAmG_Yk8GJJRygZ_1ttqOVjbq3Q9cV7-azcevNm8pj7ECyOqwXbBMkwqxMxsHrxY2XnzLzEFkASL0lf3V_4aHlEt_WnFOD6AnW62wEOCK50e9m2SrvlxNITdzycX3y7_Au-h5oY |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9NADLfWIQEvE98ExggIeCIiyV2-HiY0DaaOtntAG9pbdndxRGFJujaF9Z_a34idJoU9lLc9JUocKzrbdz-fzzbAGy1oUSMk7WSBK8lB8dDRQntOkMk8i7WRUczZyKOjsH8iv5wGpxtw1eXC8LHKbk5sJuqsMrxHzk66ZO8kcD9OLhzuGsXR1a6FxlItBrj4TS7bbPfwE8n3re8ffD7e7zttVwHHyMStHREajLw8iE0WZ7GUyjV5oogzJjoyRuRBZLwMRe76JncT5ZmcvkNf5jLQQqIgvj24JQWZJmem73v_lKtq4Xa7Y9XW9CSM8YE721fKixhwhdfWwN53PoHZK4rZepDbLHYH92CrRan23lKt7sMGlg_g9qiNwz-EwTeaIuvKnKtL5-u4nl-OC6XtcWnz2brJDDO7mtJ9Pm26-SzstgSvPVyQ8lRmUfM9zn9iMVaP4ORGBvAxbJZViU_BRkPekkrQqBCl0H6iyVtE8rKEoWscWfC-G6jUtDXLuXXGedrEzoMwvTauFrxbkU-WxTrWEb6mUV_RcInt_t4w5WeEYWRMsO-XZ8EOCSUt8Uexjst2J6-0tfxZ-ldPLXi1ek02y4EYVWI1ZxouYsSV4Cx4spTz6l98clgJhoXP_s_8JdzpH4-G6fDwaPAc7hLHJlPS97dhs57O8QVBpVrvNPppw9lNG8Qfad0iHw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-tQ5p4QXyTMUZAwBPRktj5ekBo2qg62k0IMbS3zHZsUbYkpU1h_df467hLncIeytueYiWOE_nu7N_Z598BvJIMJzVE0l4R-RwdlEB7ksnAiwpuilQqnqR0Gvn4JB6c8o9n0dkG_O7OwlBYZTcmtgN1UStaIycnnZN3Evl7xoZFfDrsv5_88CiDFO20duk0lioy1Itf6L7N3h0doqxfh2H_w5eDgWczDHiKZ37jsVjpJDBRqoq0SDkXvjKZwK_oTCZKMRMlKig0M36ojJ-JQBl8T4fc8Egyrhm224NbCUtSsrH0IPiHuspCb7t6Zfk9EW_sUZb7WgQJga_42nzY-0bRmL2ynK0HvO3E178LdyxidfeXKnYPNnR1H7aO7Z78Axh-xeGyqdWluPI-j5v51bgU0h1XLsXZTWa6cOspls20zeyzcC0drztaoCLVatFQWc8vdDkWD-H0RjrwEWxWdaWfgKsVek4i00rEmjMZZhI9R40eF1N4TRMH3nYdlSvLX05pNC7zdh89ivNr_erAm1X1yZK4Y13Fl9jrqzpEtz3YH-V0D_EMTxEC_gwc2EWh5JX-Xq5rZaeTV25HgVn-V2cdeLF6jPZLmzKi0vWc6hChEbHCOfB4KefVv4TovCIki7f_3_hz2EJTyEdHJ8OncBsbbA9NhuEObDbTuX6GqKmRu616unB-0_bwB_gXJlU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Venetoclax-Rituximab+in+Relapsed+or+Refractory+Chronic+Lymphocytic+Leukemia&rft.jtitle=The+New+England+journal+of+medicine&rft.au=Seymour%2C+John+F&rft.au=Kipps%2C+Thomas+J&rft.au=Eichhorst%2C+Barbara&rft.au=Hillmen%2C+Peter&rft.date=2018-03-22&rft.eissn=1533-4406&rft.volume=378&rft.issue=12&rft.spage=1107&rft_id=info:doi/10.1056%2FNEJMoa1713976&rft_id=info%3Apmid%2F29562156&rft.externalDocID=29562156 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon |